XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill
The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows:
(in millions)Total
Beginning balance$287.4 
Goodwill impairment
(0.8)
Translation adjustments(0.3)
Ending balance$286.3 
The Company recognized a goodwill impairment charge of $0.8 million during the nine months ended September 30, 2024 related to the goodwill allocated to the Myriad International reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statements of Operations. See Note 18 for further discussion.
As of September 30, 2024, goodwill for the Pharmacogenomics reporting unit (formerly referred to as Mental Health) was approximately $121.0 million, which represents approximately 42.3% of total recorded goodwill. On November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including the Company's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. The Company is still assessing the full impact of this policy change on its long-term forecasts; however, goodwill recorded in connection with this reporting unit may be at risk of impairment. The reporting unit was last quantitatively tested for goodwill impairment as of October 1, 2020, at which time the fair value of the reporting unit was in excess of the carrying value by 12%. As more information becomes available about the impact of the coverage decision by UnitedHealthcare, or if other adverse events occur, the Company may be required to record a goodwill impairment charge, which could have a material impact on the financial statements. See Item 2. Business Updates and Item 1A. Risk Factors for additional information.
Intangible Assets
Intangible assets consist of amortizable assets of developed technologies, internal-use software, customer relationships, and trademarks, as well as in-process internal-use software that is not yet being amortized. During the nine months ended September 30, 2024, the Company completed the sale of its EndoPredict business, including certain developed technologies with a net book value of approximately $13.1 million. See Note 18 for further discussion about the sale of the EndoPredict business.
The following summarizes the amounts reported as intangible assets:
(in millions)Gross
Carrying
Amount		Accumulated
Amortization		Net
At September 30, 2024
Developed technologies$603.3 $(316.9)$286.4 
Internal-use software1.6 (0.5)1.1 
Internal-use software (in-process)18.8 — 18.8 
Customer relationships1.6 (0.3)1.3 
Trademarks6.1 (1.2)4.9 
Total intangible assets
631.4 $(318.9)312.5 
(in millions)Gross
Carrying
Amount		Accumulated
Amortization		Net
At December 31, 2023
Developed technologies$626.1 $(295.3)$330.8 
Internal-use software
0.8 (0.1)0.7 
Internal-use software (in-process)
11.2 — 11.2 
Customer relationships1.6 (0.2)1.4 
Trademarks6.1 (0.7)5.4 
Total intangible assets$645.8 $(296.3)$349.5 
The Company recorded amortization expense during the respective periods for these intangible assets as follows:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2024202320242023
Amortization of intangible assets$10.5 $10.7 $31.9 $32.0